CLS makes progress in prostate cancer in Europe and the US
Clinical Laserthermia Systems has treated its first prostate cancer patients in Italy and secured additional orders and agreements in the US. In addition, the...
Respiratorius’ US patent application reopens
After the initial rejection of Respiratorius' patent application, the US Patent and Trademark Office's Patent Trial and Appeal Board has now sided with the...
BiBB’s CEO: “Patient cases fortify our confidence in EndoDrill”
BiBBInstruments' cancer biopsy device, EndoDrill, has earned high praise from physicians who conducted the first clinical cases at Karolinska University Hospital in Stockholm, Sweden....
Prolight Diagnostics’ collaboration with G&H | ITL propels development
Prolight Diagnostics have appointed G&H | ITL for the development of its innovative point-of-care system, Psyros. The development project started in early 2023 and...
Abliva’s mission to become mitochondrial medicine powerhouse
Abliva’s CMO Magnus Hansson attended the 8th annual meeting of Mitochondrial Medicine – Therapeutic Development in March. The conference brings together leaders in translational...
BioInvent deepens collaboration with MSD
BioInvent has signed a new clinical collaboration and supply agreement with MSD. The agreement covers the evaluation of BioInvent’s anti-TNFR2 antibody BI-1910 in combination...
Prolight’s COO comments on partnership with FlexMedical Solutions
Prolight Diagnostics has appointed FlexMedical Solutions as contract manufacturing partner for the disposable cartridge in the Psyros point-of-care system. Prolight's COO, Karl Bullen, has...
Chordate comments on Q4 and case report
Chordate Medical has published the year-end report for 2023, which showed an increase in sales compared to the previous year. The company has also...
Lipum seeks patent protecting inflammation-driven cancer treatment
Lipum has submitted an international patent application for SOL-116 as a treatment for inflammation-driven cancer. The patent application is based on the company's research...
Synact focuses on pushing forward rheumatoid arthritis project
SynAct Pharma is intent on making a turnaround after posting disappointing study results with lead asset resomelagon. The Swedish biotech is conducting a directed...